Plos One:复律后全血基因表达区分房颤和窦性心律

2018-03-25 李伟超 “罂粟花”微信号

这项研究表明,SLC25A20,PDK4和NT-proBNP作为生物标志物可区分房颤与窦性心律的增量效用。AF期间SLC25A20和PDK4的表达升高表明AF中能量代谢的重要作用。

背景

房颤动(AF)患者恢复窦性心律的治疗方案限制了长期复律成功率。 基因表达谱可能提供AF病理生理学的新见解。

通过比较电复律(ECV)前后的全血基因表达来识别生物标志物并改善我们对AF病理生理学的理解。

方  法

在46例持续性房颤患者接受ECV治疗后,在成功复律前1-2小时和复律后4至6周时收集全血样本。 将配对的样品送入基因芯片中和血浆生物标志物进行比较。

结  果

在所测试的13,942个基因中,SLC25A20和PDK4的表达与AF的相关性最强。心脏复律后,SLC25A20和PDK4表达分别下降0.8(CI 0.7-0.8,p = 2.0x10-6)和0.7(CI 0.6-0.8,p = 3.0x10-5)倍。心脏复律后,NT-proBNP浓度中位数从127.7 pg / mL降至44.9 pg / mL(p = 2.3x10-13)。与单独的NT-proBNP相比,结合型NT-proBNP和基因表达(NT-proBNP + SLC25A20曲线下面积= 0.88,NT-proBNP + PDK4AUC = 0.86)的AF辨别模型具有较高的判别能力。此外,与其他模型相比,包括NT-proBNP,SLC25A20和PDK4的模型显着提高AF辨别(AUC = 0.87,净重新分类指数> 0.56,p <5.8x10-3)。我们验证了17名患者独立样本中SLC25A20和PDK4与AF之间的关联性。

结  论

这项研究表明,SLC25A20,PDK4和NT-proBNP作为生物标志物可区分房颤与窦性心律的增量效用。AF期间SLC25A20和PDK4的表达升高表明AF中能量代谢的重要作用。

原始出处:

Raman K, Aeschbacher S, Bossard M, et al. Whole Blood Gene Expression Differentiates between Atrial Fibrillation and Sinus Rhythm after Cardioversion[J]. Plos One, 2016, 11(6):e0157550.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1790130, encodeId=fb691e9013084, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Wed Jan 23 22:45:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348063, encodeId=a1d91348063d0, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Tue Mar 27 01:45:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476261, encodeId=c20214e62614c, content=<a href='/topic/show?id=1abce558582' target=_blank style='color:#2F92EE;'>#窦性心律#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75585, encryptionId=1abce558582, topicName=窦性心律)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e147265575, createdName=paperyu, createdTime=Tue Mar 27 01:45:00 CST 2018, time=2018-03-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1790130, encodeId=fb691e9013084, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Wed Jan 23 22:45:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348063, encodeId=a1d91348063d0, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Tue Mar 27 01:45:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476261, encodeId=c20214e62614c, content=<a href='/topic/show?id=1abce558582' target=_blank style='color:#2F92EE;'>#窦性心律#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75585, encryptionId=1abce558582, topicName=窦性心律)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e147265575, createdName=paperyu, createdTime=Tue Mar 27 01:45:00 CST 2018, time=2018-03-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1790130, encodeId=fb691e9013084, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Wed Jan 23 22:45:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348063, encodeId=a1d91348063d0, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Tue Mar 27 01:45:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476261, encodeId=c20214e62614c, content=<a href='/topic/show?id=1abce558582' target=_blank style='color:#2F92EE;'>#窦性心律#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75585, encryptionId=1abce558582, topicName=窦性心律)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e147265575, createdName=paperyu, createdTime=Tue Mar 27 01:45:00 CST 2018, time=2018-03-27, status=1, ipAttribution=)]

相关资讯

Lancet:献血对身体到底有没有害,间隔多久献一次更安全?

对于捐献全血频率的限制主要是为了保障捐献者的健康。然而,在允许捐献的最高频率中,血液服务发生很大的变化。现研究人员将英国的标准做法与其他国家的较短的捐献间隔进行比较。